Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07218341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Recruiting
Start date
March 9, 2026
Completion date
December 31, 2032
Enrollment
150 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoma, small lymphocytic